Interview With Joël Brierre

We hope that YOU, the psychedelic investor, were able to gain some value from this! 🧠📈 Feel free to drop a comment! 💬 Also, you can support the channel by liking the video and checking out the links below.👇🏼 Appreciate you. 🙏🏼

There’s a SHROOM BOOM on its way. Psychedelic companies are IPOing left and right and along with them are the top 5 psychedelic stocks to buy in 2020! On this list we got:

Revive Therapeutics (RVV), Numinus (NUMI), Field Trip (FTRP), Compass Pathways (CMPS), and last but not least…MinDMed (MMEDF).

Beat by: Prod. Riddiman
Stream beats on:
Spotify: https://spoti.fi/2u4ZS7R
Apple Music: https://apple.co/2GIxb8j
Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!

On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.

Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.

In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.

Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/

CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/

MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#FieldTripHealth #Cybin #Mydecine

In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

Enjoy the episode!

Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Cybin #Psilocybin #Psychedelics